Webnot find any AGA, while LB found 64 AGA (65%) in this group. Also LB did not detect ctDNA or no AGA were reported in 74 pts, while TB was able to find 20 AGA (27%) in this group. Fifty-four pts received tar-geted therapy in the first-line setting based on genotyping results: 40/ 54 (74%) were guided by LB NGS versus 14/54 (26%) guided by TB NGS. WebAntitumor activity and safety in adv/met NSCLC pts with AGAs are encouraging. The ongoing phase 2 TROPION-Lung05 trial (NCT04484142) is assessing Dato-DXd at 6 …
LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients …
Web22 feb. 2024 · Methods: In this study, 221 tumor tissues and 174 plasma samples from NSCLC patients were analyzed by hybridization capture-based next-generation … WebPatients with BRAF V600-mutated metastatic NSCLC were selected. Current/previous participants in BRAF-related trials were excluded. Onset of metastatic NSCLC defined a patient's index date, which had to occur ≥6 months before the chart review date. Analyses were descriptive, including Kaplan-Meier analyses for overall survival (OS). he gives wisdom liberally
ESMO Breast Cancer Congress 2024 OncologyPRO
Web5 sep. 2024 · Non-small cell lung cancer (NSCLC) is a term that includes a variety of different lung cancers, most notably adenocarcinoma, squamous cell carcinoma, … WebThese investigators, based at MD Anderson, compared outcomes in patients with advanced NSCLC with targetable genomic alterations detected by ctDNA or tumor-based NGS and treated with FDA-approved... WebBackground Pts with adv/met NSCLC with AGAs derive limited benefit from existing treatments once tyrosine kinase inhibitors (TKIs) and platinum chemotherapies fail. Dato … he gives us all his love